Sanofi-Synthelabo
<<<


2004:

: 2.193 :
  +18,4%
  +11,9%
[1]: +27,1 %

 

,


2004
- 26,5% 10 ( 69,5% )
- 3,4%
- Plavix®, Aprovel®, Ambien® Eloxatine®:
--Plavix®: 39,2% 63,4 %
--Aprovel®/Avapro®: 16,8% 20,4%
--Stilnox®/Ambien®: 16,6%
--Eloxatin®: 53,3% .
- 2 Plavix®, Aprovel®, Ambien® Eloxatin® 2003

[3] 2004

" , Sanofi-Synthelabo , , " Jean-Francois Dehecq.


2004: +18,4%
Sanofi-Synthelabo 2004 2.193 , 18,4% (+11,9% ) . 6,4 , .

2004 :



, 2004 1.269 , 10,9% (+9,6% ).
, 2004 ( Plavix® Avapro® Bristol-Myers Squibb) 538 , 34,2% . , +14,2% .
, 2004 386 , 25,7% (+17,0% ).
2004: 26,5% 10
2004 10 1.525 , 26,5% (+18,5% ) 69,5 % 65,1% 2003 ( ).

2004
Plavix® ( Bristol-Myers Squibb) 394 , +39,2% . Bristol-Myers Squibb, Plavix® 37,5%.
Stilnox®/Ambien/Myslee® 345 , 16,6% .
, Ambien® 289 (+19,9% ) .
, ( 51%) Myslee®, , 9 .
Eloxatin® 256 , 53,3% . Eloxatin® 147 (+75,0% ) 109 (+31,3% ).
Aprovel® 188 , 16,8% . Bristol-Myers Squibb, Aprovel® 21,4%.
Xatral®/Uroxatral® 72 , 50,0% . Uroxatral® .
10 , , 668 2004, 3,4% .

[5] 2004: +27,1%
2004, , 2.826 , 27,1 % .

Plavix®/Iscover® 2004: +63,4%


2004 Aprovel®/Avapro®/Karvea® 324 .
, Avapro® 2004 17,5%7 . Avapro® 13,4% .


, :
- Taisho 2006 Ancaron (),
- - .
, Plavix® 24 2004.

Eloxatin
7 2004 Eloxatin® , , " 5- " ( 1 2 ).
12 2004 Eloxatin® 5-/ 1 .
19 2004 , , Eloxatin® .

Dronedarone
16 2004 III (EURIDIS ADONIS): dronedarone .

AcompliaTM (Rimonabant)
9 2004, (American College of Cardiology) RIO-LIPIDS STRATUS US AcompliaTM .

Xatral/Uroxatral®
25 2004 ALFAUR (ALFuzosin in Acute Urinary Retention) 19 (European Association of Urology).

Aventis
- 9 2004 Aventis
- 15 2004 Aventis
- 19 2004 12
- 5 2004 (Federal Trade Commission) Aventis
- 9 2004 (effectiveness) Securities and Exchange Commission (SEC)
- 12 2004
- 13 2004 GlaxoSmithKline, Aventis, Arixtra Fraxiparine ( Notre-Dame de Bondeville) 453 .
- 15 2004 5 2004 0,97 2003 ( Sanofi-Synthelabo 1,02), .


1 3 2004

10

Plavix®, Avapro® Ambien® (IMS NPA 1 3 2004 retail + mail order + long term care) ( )


.
, " ".
, , , .
: , - ( , , ).
.
:
- , . .
- , , .
, .

1 3 2003 1 3 2003

Sanofi-Synthelabo ( ) ,
Bristol-Myers Squibb Plavix ®/Iscover ® (clopidogrel) Aprovel ®/Avapro ®/Karvea ® (irbesartan), Fujisawa Stilnox®/Myslee® (zolpidem), Organon Arixtra® (fondaparinux)) . Sanofi-Synthelabo .


1 3 2004 1 32004

7 COB 2002-04, .

 

 

PAGE